Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported that 67 patients have enrolled in the potentially pivotal phase 2 globally cited clinical study comparing drug candidate Berubicin’s effectiveness to second-line standard-of-care chemotherapy drug Lomustine. “The  company plans to have more than 200 patients participate in the clinical trial on a 2:1 randomization schema between those receiving Berubicin … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Pleased with Early Results from Global Clinical Trial”

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of the most aggressive primary brain cancers. “The drug, Berubicin, is an anthracycline chemotherapy agent … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History”

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward”